Medscheme released updated MEDICINE EXCLUSION LIST APRIL 2023

By HEOR Staff Writer

April 10, 2023

Some items listed as REQUIRING PRE-AUTHORISATION:

  • Forxiga (Dapagliflozin)
  • Byetta (Exenatide)
  • Janumet (Metformin/Sitagliptin)
  • Onglyza (Saxagliptin)
  • Januvia (Sitagliptin)
  • Galvus (Vildagliptin) + including Metformin combinations
  • Liptruzet (Atorvastatin/Ezetimibe)
  • Ezetrol (Ezetimibe)
  • Inegy(Ezetimibe/Simvastatin)

Details regarding the EXCLUDED ITEMS:

  • Trulicity (Dulaglutide)
  • Jardiance (Empagliflozin)
  • Xultophy (Insulin Degludec and Liraglutide)
  • Soliqua (Insulin Glargine and Lixisenatide)
  • Victoza (Liraglutide)
  • Synjardy (Metformin and Empagliflozin)
  • Ozempic (Semaglutide)
Reference url

Recent Posts

Accelerating Access to Latin America Innovative Therapies Through Collaboration and Innovation

By HEOR Staff Writer

November 25, 2025

Accelerating Access to Latin America Innovative Therapies In this update we outline a strategic vision for transforming Latin America's healthcare systems through innovation, collaboration, and equitable access, with a stron...
Weight Loss: Advances in Hormone-Based Obesity Treatments

By HEOR Staff Writer

November 12, 2025

Advances in Hormone-Based Pharmacotherapies for Obesity Hormone-based obesity treatments are improving the approach to weight management by targeting the body's neurometabolic systems. A recent
Advancing Kidney Transplant Transparency Through Patient Involvement

By HEOR Staff Writer

November 6, 2025

Enhancing Kidney Transplant Transparency In a